Tailored lifestyle intervention for obese children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Dyn@mo intervention focuses on children and adolescents aged 6 to 17 years with cardiometabolic risk factors, particularly obesity. It aims to promote physical activity and reduce sedentary behavior by utilizing wearable sensors to gather data on mobility and activity levels. This data helps healthcare professionals provide personalized counseling to improve the children's cardiometabolic health. The study is currently in the implementation phase at CHU Sainte-Justine in Quebec, Canada.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* children ages 6 to 18 years of age with a BMI \> 95th percentile for age and sex

Exclusion Criteria:

* children with a physical or psychological condition that would impair their ability to participate in physical activity

Where it's running

• CHU Sainte-Justine
  Montreal, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Melanie Henderson
• Phone: 514-345-4735

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mechanical ventilation strategy to protect the lungs in obese adults during laparoscopic or robotic surgery

  This trial tests whether a specific intraoperative PEEP approach that uses transpulmonary pressure to limit lung power can improve breathing after surgery for adults with BMI 35 or higher undergoing laparoscopic or robotic procedures.

  Recruiting The University of Texas Medical Branch, Galveston · Galveston, Texas · NCT07774065

• Combined resistance training and high-protein diet to help frailty in sarcopenic obesity women

  This trial tests whether adding supervised resistance exercise to a high-protein diet helps frailty in obese, sarcopenic women.

  Recruiting Cairo University · El-Sheikh Zayed City · NCT07627919

• SA030 Injection in Adults with Overweight or Obesity (Phase 1)

  This first-in-human study tests a single dose of SA030 to see if it is safe and well tolerated in adults who are overweight or obese.

  Recruiting at 2 sites Phase 1 Suzhou Siran Biotechnology Co.,Ltd. · Brisbane, Queensland and 1 other locations · NCT07479862

• Weekly injections of GIP (NNC0480-0389) plus amylin (cagrilintide) to see stomach side effects in adults with overweight or obesity

  This trial tests whether adding a GIP injection (NNC0480-0389) to weekly cagrilintide changes stomach-related side effects in adults with overweight or obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Harrow, Middlesex · NCT07411560

• MB-1 vs placebo for weight and metabolic health in adults who are overweight or obese

  A study will test MB-1 to see if it helps adults who are overweight or obese lose weight and improve metabolic health compared to a placebo.

  Recruiting Arrae · London, Ontario · NCT07363148

• Testing HM17321 injections to find safe dose ranges in healthy and obese adults

  This study will try single and multiple doses of HM17321 injections in healthy adults and adults with obesity to see if they are safe and how the body processes the drug.

  Recruiting Phase 1 Hanmi Pharmaceutical Company Limited · Cincinnati, Ohio · NCT07219589

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.